Hypotension associated with the rapid infusion of human serum albumin products was first recognised in Australasia in the early 1970s. An association with the angiotensin converting enzyme inhibitor class of drugs (ACE-I) followed, leading to a proposed mechanism involving bradykinin generation through pre-kallikrein activator (PKA) presence in the infused fluid. The newer generation albumin products (Albumex ® ) contain very low concentrations of PKA and are generally thought safe to use in most patient populations. Anecdotal reports of paradoxical hypotension with rapid infusion of 4% albumin in our department led to an audit of practice over three months. Four out of 36 patients (11%) who received 4% albumin intravenously experienced paradoxical hypotension. Three of these patients were taking . There was no observed hypotension associated with intravenous infusion of crystalloid fluid. We believe 4% albumin should be used with caution, particularly in those patients receiving ACE-I preoperatively.
The controversy over which intravenous fluid is best suited to use in critically ill patients continues worldwide. This debate has been heightened by the advent of the Cochrane database meta-analysis which suggested there may be an increased incidence of mortality in albumin-treated patients 1 . In the aftermath of this publication, strong statements were made about the conclusions drawn and the methodology involved 2 . Many even questioned the need to study this issue further. In direct contrast to this sentiment, the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group are ready to address this issue with a large randomized clinical trial ready to be launched in the near future.
The Christchurch Hospital Department of Intensive Care Medicine has favoured the use of crystalloid fluids to the virtual exclusion of colloidal substances. The advent of a cardiothoracic service in 1997 saw an alliance formed between the established intensive care facility and the incoming surgical service. As a result of this process, the use of 4% albumin was introduced as the agent of choice for volume replacement in cardiac surgical patients, during the postoperative phase.
One of the two surgical teams, after consultation with senior representatives of the Department of Intensive Care Medicine, subsequently elected to change to a crystalloid fluid. This division in fluid policy led to a number of anecdotal observations on the part of nursing and medical staff alike. One of the most striking of these was an apparent paradoxical hypotension witnessed during the infusion of 4% albumin. Similar hypotensive reactions had previously been reported in Australasia in the setting of the administration of less pure albumin preparations, particularly in those patients concurrently taking angiotensin converting enzyme inhibitors (ACE-I) 4, 5 . The "strength" of these observations led some medical staff in our department to alter their clinical practice, with avoidance of 4% albumin being practiced in patients who had been on ACE-I preoperatively. In an effort to document more clearly the response of blood pressure to these disparate fluids, an audit of practice was conducted.
METHODS
A prospective audit was undertaken over a threemonth period from November 2000 to January 2001. A three-page data collection form covering pre-intensive care, intensive care and convalescent events was completed by the admitting intensive care registrar, the attendant intensive care nurse and the cardiothoracic ward staff respectively. The audit form, in tick-box format, was present at the bedside during the patient's stay in intensive care, ensuring that information was recorded contemporaneously.
The standard fluid practice in our unit is to administer a maintenance infusion of crystalloid (80 ml per hour in a 70 kg patient), with additional boluses of fluid given at the discretion of the attendant medical staff. A fluid bolus would typically consist of a 250 to 500 ml aliquot infused over 10 to 30 minutes. Nursing staff were asked to indicate whether at any stage there appeared to be a temporal relationship between commencing an infusion of a fluid bolus (4% albumin or 0.9% saline) and a detectable decrease in blood pressure. A review of the patient's observation chart was undertaken by the primary author to document the magnitude and nature of any hypotensive episodes noted.
Those patients taking ACE-I as part of their preoperative pharmacotherapy were routinely administered a dose on the morning of surgery.
Results generated from the audit were analysed using Graphpad Prism 3.0 with a level of significance set at P<0.05.
RESULTS
Seventy-one patients underwent cardiac surgery during the audit. Two patients with chronic renal disease were excluded because their postoperative fluid management was complicated by intermittent dialysis. Thirty-three (48%) of the patients received crystalloid fluid for resuscitation during the postoperative phase. In no instance was a crystalloid bolus thought to aggravate or precipitate a fall in blood pressure. Fifteen (50%) of the patients in the crystalloid group had been prescribed a member of the ACE-I class of drugs preoperatively.
Thirty-six patients (52%) received 4% albumin as their primary resuscitation fluid. Four (11%) of these patients were judged by nursing staff to have experienced a hypotensive episode in relation to starting 4% albumin. In these four patients the hypotension-albumin association was observed to be robust: there was a clinically significant drop in blood pressure (↓systolic BP 15 to 20 mmHg); the blood pressure increased when the infusion was discontinued, and this effect was repeatable on re-challenge in three of the four patients. Nine of the 36 patients (25%) receiving colloidal resuscitation fluid were also prescribed a member of the ACE-I drug class preoperatively. This subgroup included three of the four patients thought to have reacted adversely to a 4% albumin infusion (Table 1) .
Hypotension concurrent with infusion of 4% albumin was significantly associated with use of an ACE-I preoperatively (P=0.04, chi-square test). All four patients were male but this finding did not reach significance (P=0.16, chi squared). There was no correlation with operative technique (cardiopulmonary bypass versus no bypass) or with category of surgery (urgent versus elective). The four patients who displayed paradoxical hypotension were a diverse group when analysed for other factors including: age (range =39 to 78, mean=59 years), duration of intensive care admission (range=24 to 48, mean=30 hours), fluid balance in intensive care (range=235 to 4204 ml, mean=3006 ml), need for inotrope or vasopressor support (measured in hours of agents used range=0 to 92, mean=30 hours), weight gain during postoperative stay (range=0.6 to 9.5 kg, mean 5.3 kg) or days to discharge from day of surgery (range 5 to 9, mean 6.5). When the outcome of the two groups (albumin versus crystalloid) was analysed, the 4% albumin group spent less time in the intensive care ward, received less fluid in total and had less of a positive fluid balance. They were less likely to require inotrope-vasopressor support and required less frusemide in the convalescent period than their counterparts receiving crystalloid. All of these endpoints attained statistical significance ( Table 2 ). This advantage however was not sustained and there was no significant difference in length of hospital stay ( Table 2 ). The study was not powered to look at mortality or morbidity. There were two deaths in the crystalloid group (not statistically significant).
DISCUSSION
The purpose of this audit was to document events surrounding the use of two differing fluids in the setting of volume resuscitation in the postoperative phase of cardiac surgery, particularly the anecdotal observation of paradoxical hypotension associated with the infusion of a bolus of 4% albumin. Four patients undergoing surgery during the period of the audit appeared to have paradoxical hypotension upon rapid infusion of 4% albumin. In three of these patients the indication for administration of a bolus of albumin was "volume administration" and not hypotension per se. The merit of volume replacement in a normotensive patient is open to debate, however it makes it more likely that the observed hypotension was due to the albumin infusion rather than any underlying haemodynamic compromise.
Hypotension associated with infusion of albumin products is not a new finding. In the early 1970s Stable Plasma Protein Solution (SPPS) was noted by a group of Australian clinicians to be associated with hypotension when infused rapidly 6 . This was thought to be due to high levels of pre-kallikrein activator (PKA) in SPPS which led to an in vivo generation of bradykinin. Bradykinin, a potent vasodilator, is normally rapidly inactivated by angiotensin converting enzymes in the pulmonary vasculature. The manufacturing process of SPPS was changed in order to reduce PKA content, but in the early 1990s reports again surfaced of hypotension associated with albumin infusions. These incidents were predominantly case reports in which the ACE-I class of drugs appeared to be a central component 4 . The known effects of ACE-I strengthened the earlier bradykinin hypothesis. It was against this background that a consensus statement issued by the Subcommittee of the Victorian Drug Usage Advisory Committee advised against the use of SPPS in cardiac surgery, and suggested a synthetic colloid as the solution of first choice 5 . Commonwealth Serum Laboratories, which produce albumin products in Australasia, recommended that hypovolaemic hypotension in patients taking ACE-I should be managed with an alternative plasma volume expander, such as Normal Serum Albumin 4 .
The current 4% albumin solution being used in Australasia is a product of chromatographic purification, which is said to reduce PKA concentration in the solution to <1 IU/ml. This represents a considerable decrease over earlier preparations which contained up to 50 IU/ml. To date there have been few reports forwarded to the manufacturers of Albumex ® of an In our audit, although the numbers were small, there was a significant association between the preoperative use of ACE-I and paradoxical hypotension in patients receiving 4% albumin. The original paradigm of PKA activity generating bradykinin in vivo might still be relevant in our study population, particularly if one of two scenarios holds true. Firstly these patients represent a population at risk for haemodynamic compromise and therefore any additional hypotensive factors (e.g. bradykinin) may exert an amplified effect. Secondly it has been suggested that the PKA assay itself may underestimate the amount of PKA in a given batch (Personal communication, Dr Jim Faed. Director, Blood Transfusion Services, Dunedin Hospital, Dunedin, New Zealand. January 2001).
It is more difficult to explain the hypotension noted in the patient who was not taking an ACE-I before his surgery. Explanations might include a large amount of PKA, a true hypersensitivity reaction or an as yet unknown mechanism. The incidence of true hypersensitivity reactions to human albumin is relatively low (0.01% per unit infused), however this mechanism cannot be excluded 7 .
Both the non-randomized design of this observational study and the relatively small number of patients enrolled do not allow us to form any opinion as to which fluid choice might be "best" in postcardiac surgical patients, or for that matter in general intensive care patients. However it would appear that 4% albumin did not impact negatively on our study population, at least during the intensive care phase of therapy ( Table 2 ). This would seem to suggest a short-lived adverse reaction to 4% albumin solution in a few perhaps predisposed patients, rather than a global effect on all patients receiving this fluid. Given that ACE-I may predispose to hypotension in patients receiving 4% albumin, it may be inappropriate and perhaps dangerous to continue aggressive fluid administration with 4% albumin in these patients.
In the postoperative cardiac patient one could make a case, based on the above evidence, to avoid the use of 4% albumin in that sub-population exposed to ACE-I preoperatively. The earlier dictum of avoiding albumin products in patients on ACE-I preoperatively may still hold true for the newer purified albumin derivatives. At the very least, patients receiving infusions of 4% albumin should be observed closely for paradoxical hypotension. Furthermore, paradoxical hypotension associated with rapid infusion of 4% albumin may be present in the wider intensive care population. Future studies on the use of colloid solutions in the general intensive care setting may elucidate this issue further.
